html5-img
1 / 22

Pharmacotherapy in Older Adults

Pharmacotherapy in Older Adults. Janet Cho, PharmD , CGP Clinical Pharmacist, Keck Medical Center of USC Bradley R. Williams, PharmD, FASCP, CGP Professor, Clinical Pharmacy & Clinical Gerontology. Prescription Medication Use. Gu Q, et al., NCHS Data Brief No. 42, 2010.

rayya
Télécharger la présentation

Pharmacotherapy in Older Adults

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmacotherapy in Older Adults Janet Cho, PharmD, CGP Clinical Pharmacist, Keck Medical Center of USC Bradley R. Williams, PharmD, FASCP, CGP Professor, Clinical Pharmacy & Clinical Gerontology

  2. Prescription Medication Use Gu Q, et al., NCHS Data Brief No. 42, 2010

  3. Why Are We Concerned? • Older adults account for 49.8% of hospital admissions due to adverse drug events1 • Rate is greatest for age 85+ years • 87% due to hypoglycemics, anticonvulsants, warfarin, digoxin, theophylline, lithium • Adults age 50+ account for 51.1% of ED admissions for adverse drug events2 • CNS drugs (28.8%), blood modifiers (22.6%), cardiovascular meds (18.1%) are most common 1Budnitz, et al, JAMA, 2006; 2The DAWN Report, 2011

  4. Why Are We Concerned? • Medicare hospital readmissions1 • 30 days (19.6%); 60 days (28.2%) • Heart failure, pneumonia, COPD, psychosis are most common discharge diagnoses • Preventable medication errors2 • Renal and hepatic function • Drug interactions • Lack of individualized therapy 1 Jencks, et al., NEJM, 2009; 2 Kohn, et al. Institute of Medicine, 2000

  5. Age-associated Issues • Physiologic changes affect both pharmacokinetics and pharmacodynamics • Reduced physiologic reserve narrows the margin for error • Polymedicine increases the risk for adverse reactions and drug interactions • Multiple providers and self-care both increase the risk for inappropriate medication use

  6. Physiologic Changes • Body composition • Increase in body fat (% of total body weight) • Women: 33% to 48% • Men: 18% to 36% • Decrease in body water • Reduced serum albumin • Increased α1-acid glycoprotein • Decreased lean body mass

  7. Physiologic Changes • Gastrointestinal tract • Increased gastric pH • Reduced intestinal blood flow • Impaired active & passive transport mechanisms • Delayed gastric emptying • Slowed GI motility

  8. Physiologic Changes • Liver • Decreased hepatic mass • Reduced hepatic blood flow • Kidney • Loss of functioning nephrons • Reduced renal blood flow • Decreased tubular secretion • Decreased glomerular filtration

  9. Drug Absorption • Primarily a passive process that occurs in the small intestine • Rate of absorption may be slowed • Delayed, lower peak serum levels • Increased bioavailability for some hepatically metabolized drugs due to reduced first-pass effect (e.g., verapamil, labetalol, lidocaine) • Transdermal absorption is variable

  10. Drug Distribution Factors leading to altered distribution… • Decreased • Lean body mass • Total body water • Serum albumin • Cardiac output • Increased • Total body fat • α1-acid glycoprotein

  11. Drugs with Decreased Binding • Benzodiazepines • Diazepam • Lorazepam • Temazepam • Triazolam • Desipramine • Meperidine • NSAIDs • Diflunisal* • Naproxen* • Salicylates* • Phenytoin • Theophylline • Valproate* • Warfarin * >50% decrease

  12. Drug Metabolism Factors leading to altered metabolism… • Reduced liver mass and volume • Decreased hepatic blood flow • Altered enzyme activity • Sex and genetic differences • Age-associated declines • Drug interactions • Nutrition and health status

  13. Aging & CYP Activity -Cusack. Am J GeriatrPharmacother 2004;2:274-302

  14. Other Influences -O’Mahoney & Woodhouse. PharmacolTher 1994;61:279-287

  15. Drug Renal Excretion Factors leading to altered excretion… • Reduced kidney mass, number and size of nephrons • Decreased renal blood flow • Decreased glomerular filtration • Reduced tubular secretory mechanisms • Effect of disease

  16. CNS Changes • Reduced blood flow and oxygenation • Increased MAO levels • Decreased norepinephrine, dopamine • More sensitive to sedating agents • Greater sensitivity to anticholinergic agents • Increased permeability of the blood-brain barrier

  17. Cardiovascular Changes • Decreased response to catecholamines • Primarily affects ß-receptors • Increased circulating norepinephrine • Reduced cardiac output • Increased peripheral resistance • Less responsive baroreceptors

  18. Pharmacogenomic Issues • No apparent changes across the adult lifespan • Possibly some decrease in CYP 3A4 and 2A6 • Fast and slow metabolizers • N-acetyltransferase activity • Slow acetylators (autosomal recessive)

  19. Medication-related Problems • Dose too high • Dose too low • Improper medication • Contraindication • Allergy • Inappropriate for patient’s age or function • Drug interaction • Adverse drug reaction • Unnecessary medication • Duplicate • No indication • Problem resolved • Untreated indication • Patient not receiving medication

  20. Medication Risk Assessment • > 5 medications • > 12 daily doses • Narrow therapeutic index drugs • Multiple prescribers • Taking medicines for at least 3 problems • Uses multiple pharmacies • Someone brings medicines to the home • Complex regimen • At least 4 direction changes in 1 year • Any medicine taken for an unknown reason -Levy HB, Ann Pharmacother, 2003

  21. High-risk Patients

  22. Summary • Age-associated changes in pharmacokinetics and pharmacodynamics present therapeutic challenges • Interpatient variability makes it difficult to predict clinical effects with certainty • Disease, nutrition, adherence, other drugs complicate the picture • Patients benefit from a “risk management” approach

More Related